Cantor Fitzgerald Upgrades Rezolute Following FDA Pre-BLA Meeting News
Cantor Fitzgerald has upgraded its rating for Rezolute (RZLT) to 'overweight' from 'neutral,' citing the potential scheduling of a pre-BlA meeting with the U.S. Food and Drug Administration (FDA). The company's lead candidate, ersodetug, is being developed for congenital hyperinsulinism (cHI), a rare condition marked by abnormally low blood sugar levels. The upgrade reflects optimism that regulatory progress could accelerate development timelines or provide clarity on the drug’s path to approval. Analysts believe this meeting may offer insights into how the FDA views ersodetug's potential for treating cHI, which is currently underserved in terms of therapeutic options. This move by Cantor Fitzgerald signals a positive shift in sentiment toward Rezolute and could influence investor behavior as expectations around regulatory milestones rise.
Tickers: $RZLT